VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status ; volume:14 ; number:1 ; day:6 ; month:11 ; year:2021 ; pages:1-7 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (6.11.2021), 1-7, 12.2021
- Urheber
-
Bizzaro, Francesca
Fuso Nerini, Ilaria
Taylor, Molly A.
Anastasia, Alessia
Russo, Massimo
Damia, Giovanna
Guffanti, Federica
Guana, Francesca
Ostano, Paola
Minoli, Lucia
Hattersley, Maureen M.
Arnold, Stephanie
Ramos-Montoya, Antonio
Williamson, Stuart C.
Galbiati, Alessandro
Urosevic, Jelena
Leo, Elisabetta
Cavallaro, Ugo
Ghilardi, Carmen
Barry, Simon T.
Bani, Maria Rosa
Giavazzi, Raffaella
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-021-01196-x
- URN
-
urn:nbn:de:101:1-2022012020094700735527
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bizzaro, Francesca
- Fuso Nerini, Ilaria
- Taylor, Molly A.
- Anastasia, Alessia
- Russo, Massimo
- Damia, Giovanna
- Guffanti, Federica
- Guana, Francesca
- Ostano, Paola
- Minoli, Lucia
- Hattersley, Maureen M.
- Arnold, Stephanie
- Ramos-Montoya, Antonio
- Williamson, Stuart C.
- Galbiati, Alessandro
- Urosevic, Jelena
- Leo, Elisabetta
- Cavallaro, Ugo
- Ghilardi, Carmen
- Barry, Simon T.
- Bani, Maria Rosa
- Giavazzi, Raffaella
- SpringerLink (Online service)
Ähnliche Objekte (12)
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
PARP Inhibitors in Ovarian Cancer: A Review
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials
BRCA germline mutation test for all woman with ovarian cancer?
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
PARP Inhibitors in Ovarian Cancer: A Review
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials
BRCA germline mutation test for all woman with ovarian cancer?
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
PARP Inhibitors in Ovarian Cancer: A Review
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials